Literature DB >> 27867143

Survival after percutaneous coronary intervention for chronic total occlusion in elderly patients.

Aurel Toma1, Catherine Gebhard, Michael Gick, Fadil Ademaj, Barbara E Stähli, Kambis Mashayekhi, Miroslaw Ferenc, Franz-Josef Neumann, Heinz Joachim Buettner.   

Abstract

AIMS: Few data are available on outcomes of percutaneous coronary intervention (PCI) for coronary chronic total occlusions (CTO) in very elderly patients in the drug-eluting stent (DES) era. We aimed to investigate long-term survival in a single-centre cohort of elderly patients following CTO PCI using DES. METHODS AND
RESULTS: A total of 2,002 consecutive patients who underwent PCI of a CTO at our centre between January 2005 and December 2013 were followed for a median of 2.6 years (interquartile range 1.1-3.1 years). Four hundred and nine (409) patients were older than 75 years. The absolute reduction in all-cause mortality by successful CTO PCI was numerically greater in elderly patients as compared to younger patients (22.1% vs. 7.2% at three years). In multivariate models, successful CTO PCI was significantly associated with improved survival in both elderly (adjusted hazard ratio [HR] 0.58, 95% confidence interval [CI]: 0.39 to 0.87; p=0.009) and younger patients (adjusted HR 0.59, 95% CI: 0.40 to 0.86; p=0.006).
CONCLUSIONS: In the DES era, elderly patients (≥75 years) derive a similar survival benefit from successful CTO PCI to younger patients. These findings suggest that CTO PCI, when indicated, should not be withheld from the elderly.

Entities:  

Mesh:

Year:  2017        PMID: 27867143     DOI: 10.4244/EIJ-D-16-00499

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  7 in total

1.  Outcomes of patients with periprocedural atrial fibrillation undergoing percutaneous coronary intervention for chronic total occlusion.

Authors:  Barbara E Stähli; Cathérine Gebhard; Michael Gick; Kambis Mashayekhi; Miroslaw Ferenc; Heinz Joachim Buettner; Franz-Josef Neumann; Aurel Toma
Journal:  Clin Res Cardiol       Date:  2017-08-03       Impact factor: 5.460

2.  Outcomes after percutaneous coronary intervention for chronic total occlusion according to baseline renal function.

Authors:  Barbara E Stähli; Cathérine Gebhard; Michael Gick; Miroslaw Ferenc; Kambis Mashayekhi; Heinz Joachim Buettner; Franz-Josef Neumann; Aurel Toma
Journal:  Clin Res Cardiol       Date:  2017-11-13       Impact factor: 5.460

3.  Outcomes after percutaneous coronary intervention and comparison among scoring systems in predicting procedural success in elderly patients (≥ 75 years) with chronic total occlusion.

Authors:  Ya-Min Su; Min Pan; Hai-Hua Geng; Rui Zhang; Yang-Yang Qu; Gen-Shan Ma
Journal:  Coron Artery Dis       Date:  2019-11       Impact factor: 1.439

Review 4.  Percutaneous coronary intervention for chronic total occlusion in patients aged <75 years versus ≥75 years: a systematic review.

Authors:  Noman Lateef; Muhammad Junaid Ahsan; Hafiz Muhammad Fazeel; Abdul Haseeb; Azka Latif; Omar Kousa; Mohsin Mirza; Mark Holmberg
Journal:  J Community Hosp Intern Med Perspect       Date:  2020-02-10

5.  Percutaneous coronary intervention for chronic total occlusion in octogenarians: a propensity score study.

Authors:  Recha R L Blessing; Majid Ahoopai; Martin Geyer; Moritz Brandt; Andreas M Zeiher; Mariuca Vasa-Nicotera; Thomas Münzel; Philip Wenzel; Tommaso Gori; Zisis Dimitriadis
Journal:  Sci Rep       Date:  2022-02-23       Impact factor: 4.379

Review 6.  Percutaneous Coronary Intervention in Elderly Patients with Coronary Chronic Total Occlusions: Current Evidence and Future Perspectives.

Authors:  Lei Guo; Hai-Chen Lv; Rong-Chong Huang
Journal:  Clin Interv Aging       Date:  2020-05-28       Impact factor: 4.458

7.  Effects of Altered Levels of Pro- and Anti-Inflammatory Mediators on Locations of In-Stent Reocclusions in Elderly Patients.

Authors:  Xia Li; Dianxuan Guo; Ying Chen; Youdong Hu; Fenglin Zhang
Journal:  Mediators Inflamm       Date:  2020-09-23       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.